Literature DB >> 22750097

Phosphatidylinositol 4-kinases, phosphatidylinositol 4-phosphate and cancer.

Mark G Waugh1.   

Abstract

This article focuses on the emerging roles for phosphatidylinositol 4-phosphate and the phosphatidylinositol 4-kinases in cancer. Phosphatidylinositol 4-phosphate is a common substrate for both the phosphatidylinositol 3-kinase and phospholipase C pathways, and has been implicated in the membrane targeting of proteins such as Girdin/GIV and OSBP. Alterations to phosphatidylinositol 4-kinase expression levels can modulate MAP kinase and Akt signalling, and are important for chemoresistance, tumour angiogenesis and the suppression of apoptosis and metastases. Recent improvements in high-throughput screening assays, and the discoveries that some anti-viral molecules are isoform selective phosphatidylinositol 4-kinase inhibitors have advanced the drugability of these enzymes.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22750097     DOI: 10.1016/j.canlet.2012.06.009

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  12 in total

Review 1.  Regulating cellular cyclic adenosine monophosphate: "Sources," "sinks," and now, "tunable valves".

Authors:  Michael Getz; Padmini Rangamani; Pradipta Ghosh
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2020-04-23

2.  Overexpression of phosphatidylinositol 4-kinase type IIIα is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma.

Authors:  Adeodat Ilboudo; Jean-Charles Nault; Hélène Dubois-Pot-Schneider; Anne Corlu; Jessica Zucman-Rossi; Michel Samson; Jacques Le Seyec
Journal:  BMC Cancer       Date:  2014-01-06       Impact factor: 4.430

3.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  Amplification of Chromosome 1q Genes Encoding the Phosphoinositide Signalling Enzymes PI4KB, AKT3, PIP5K1A and PI3KC2B in Breast Cancer.

Authors:  Mark G Waugh
Journal:  J Cancer       Date:  2014-10-28       Impact factor: 4.207

5.  Inhibition of PI4K IIIα radiosensitizes in human tumor xenograft and immune-competent syngeneic murine tumor model.

Authors:  Younghee Park; Ji Min Park; Dan Hyo Kim; Jeanny Kwon; In Ah Kim
Journal:  Oncotarget       Date:  2017-11-30

6.  Novel phosphatidylinositol 4-kinases III beta (PI4KIIIβ) inhibitors discovered by virtual screening using free energy models.

Authors:  Natalie M Colodette; Lucas S Franco; Rodolfo C Maia; Harold H Fokoue; Carlos Mauricio R Sant'Anna; Eliezer J Barreiro
Journal:  J Comput Aided Mol Des       Date:  2020-06-30       Impact factor: 3.686

7.  A predictive computational model reveals that GIV/girdin serves as a tunable valve for EGFR-stimulated cyclic AMP signals.

Authors:  Michael Getz; Lee Swanson; Debashish Sahoo; Pradipta Ghosh; Padmini Rangamani
Journal:  Mol Biol Cell       Date:  2019-04-24       Impact factor: 4.138

Review 8.  Mammalian phosphatidylinositol 4-kinases as modulators of membrane trafficking and lipid signaling networks.

Authors:  Emma L Clayton; Shane Minogue; Mark G Waugh
Journal:  Prog Lipid Res       Date:  2013-04-19       Impact factor: 16.195

9.  Modeling the effects of cyclodextrin on intracellular membrane vesicles from Cos-7 cells prepared by sonication and carbonate treatment.

Authors:  Peter Kilbride; Holly J Woodward; Kuan Boone Tan; Nguyễn T K Thanh; K M Emily Chu; Shane Minogue; Mark G Waugh
Journal:  PeerJ       Date:  2015-10-27       Impact factor: 2.984

10.  Identification of a novel biomarker in tangeretin‑induced cell death in AGS human gastric cancer cells.

Authors:  Silvia Yumnam; Suchismita Raha; Seong Min Kim; Venu Venkatarame Gowda Saralamma; Ho Jeong Lee; Sang Eun Ha; Jeong Doo Heo; Sang Joon Lee; Eun Hee Kim; Won Sup Lee; Jin A Kim; Gon Sup Kim
Journal:  Oncol Rep       Date:  2018-09-24       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.